The licensing tribunal opened at ten in the morning because no one wanted another night of surge before an interim decision. Adrian Vale sat with Nocturne counsel. Maira sat behind him, not beside him. Zawadi presented the Board record. Leila was there only for the technical areas she could support.
Adrian did not begin by denying everything.
“Nocturne did not create nocturnal change,” he said. “We have records years older than this company. Centralized care was built because fragmented dosing caused preventable crises.”
His lawyers submitted historical files from before the new Calm-X formulation and before the expansion of Nocturne.
The panel chair turned to Leila. “Do you dispute that?”
“No. Our lab work does not establish Nocturne as the origin of the syndrome.”
Adrian leaned forward. “Then why dismantle the only system that ever managed this risk at scale?”
“Because the origin of the syndrome and the safety of a new formulation are separate questions,” Leila said. “Access control and delayed safety reporting are separate questions again.”
The Board entered the lab summary with its limits intact: higher sensitizer marker in the current formulation, compatible adverse events under review, no claim that every episode came from that product.
Adrian attacked the decentralized alternative. “One night of emergency improvisation is not safety architecture.”
“Agreed,” Leila said. “That is why we are asking for a temporary multi-license regime with qualification, audit and shared alerts.”
One panel member asked the strongest practical question: how would several clinics prevent duplicate dosing if a patient moved between them?
“That's what our registry does,” Adrian said.
“A shared clinical ID can do that without tying identity to one provider's account,” Leila replied. “Yesterday a cross-site log already stopped a duplicate dose.”
The panel ordered the Board to define the minimum fields for portable continuity: clinical ID, current protocol, last dose, critical allergies and consent flags. Debt and marketing fields were excluded.
The hearing then moved to chronology. Zawadi placed the internal sensitization signal beside the later Board notification. The signal had been classified non-material pending study and was not reported to the regulator until after expansion began.
Adrian argued that it was not confirmed harm.
“No one is calling it confirmed harm,” the panel member said. “We are asking when the regulator received the signal.”
The gap remained.
During a break, Maira found Leila in the corridor.
“Adrian isn't a monster,” she said. “He built Nocturne after seeing clinics lose track of patients.”
“I never said he was a monster.”
“There is a narrow line between protecting a system and protecting power.”
“Which is why checks can't depend on one person always recognizing the line.”
When the hearing resumed, Adrian introduced a case from eleven years earlier. A patient had received overlapping stabilizers from three clinics with no shared record and entered crisis.
Leila understood the logic. Fragmentation had caused real danger.
“Centralization solved that,” Adrian said.
“Continuity matters,” Leila answered. “But continuity does not require one company's debt account, data gate and treatment doorway.”
Her requested remedy was a thirty-day multi-license emergency regime, shared clinical identity and direct adverse-event reporting to the Board. Nocturne could remain a supplier and technical participant. It could not remain the sole gatekeeper.
The panel granted the interim order.
For thirty days, exclusivity was suspended.
As the clerk gathered the historical exhibits, Leila saw the cover of the eleven-year-old file.
The patient name stopped her cold.
The order also required a portable-identity implementation proposal within twenty-four hours. That meant Adrian's strongest argument—duplicate dosing across fragmented clinics—would be treated as a design requirement rather than dismissed as corporate fear.
When the clerk noticed Leila staring at the old file, he asked whether she wanted a copy. She said not yet. The exhibit had been introduced for historical context, and her family relationship created another boundary she would need to disclose before using it for anything else.
Only after the hearing did she message Zawadi that the name appeared to be her mother's and ask for a formal verification route.
It was her mother's.